Info@ThinkPinkRocks.com

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi’s sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma.

Read More:
CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi’s sarcoma

Share

Leave a Reply

Solve : *
9 + 23 =